Advanced/metastatic bladder cancer: current status and future directions

被引：37

作者：

Facchini, G. ^{[1
]}

Cavaliere, C. ^{[2
]}

Romis, L. ^{[3
]}

Mordente, S. ^{[3
]}

Facchini, S. ^{[4
]}

Iovane, G. ^{[5
]}

Capasso, M. ^{[5
]}

D'Errico, D. ^{[5
]}

Liguori, C. ^{[1
]}

Formato, R. ^{[1
]}

Cicala, S. ^{[1
]}

Andreozzi, F. ^{[6
]}

Di Lauro, G. ^{[3
]}

Imbimbo, C. ^{[4
]}

Vanni, M. ^{[7
]}

D'Aniello, C. ^{[8
]}

机构：

[1] ASL NA 2 Nord SM delle Grazie Hosp, UOC Med Oncol, Pozzuoli, NA, Italy

[2] ASL NA 3 Sud Osped Riuniti Area Nolana, UOC Med Oncol, Nola, NA, Italy

[3] ASL NA 2 Nord SM delle Grazie Hosp, UOC Urol, Pozzuoli, NA, Italy

[4] Univ Federico II Napoli, Dept Urol, Naples, Italy

[5] IRCCS Fdn G Pascale, Dept Unit Clin & Expt UroAndrol Oncol, Ist Nazl Tumori, Naples, Italy

[6] Univ Naples 2, Med Oncol, Naples, Italy

[7] Hlth Manager ASL NA 2 Nord, Naples, Italy

[8] AORN COLLI Osped Monaldi Cotugno CTO, Div Med Oncol, Naples, Italy

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2020年 / 24卷 / 22期

关键词：

Bladder cancer; Chemotherapy; Prognostic factors; Immunotherapy; METASTATIC UROTHELIAL CARCINOMA; TRANSITIONAL-CELL-CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; OPEN-LABEL; FACTOR RECEPTOR; DOUBLE-BLIND; COMPARING GEMCITABINE; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT;

D O I：

10.26355/eurrev_202011_23795

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In 2015 bladder cancer was the fourth most frequent malignancy and the eighth cause of death for cancer. At diagnosis, about 30% of bladder cancer (BC) patients present a muscle-invasive bladder cancer (MIBC) and 5% a metastatic bladder carcinoma (MBC). For fit MBC patients, combination chemotherapy (CC) is the standard of care for first-line treatment. CC includes both the treatment with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) either the classical or the dose-dense MVAC regimen, and the doublet therapy with cisplatin and gemcitabine (CG). Median progression free survival (PFS) was 7 months and median overall survival (OS) was 15 months. The present review provides an update on the management of MBC, with focus on target therapies, immune checkpoint inhibition, looking for prognostic and predictive factors.

引用

页码：11536 / 11552

页数：17

共 50 条

[41] Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions
Kamatham, Saivaishnavi
Shahjehan, Faisal
Kasi, Pashtoon M.
CURRENT COLORECTAL CANCER REPORTS, 2019, 15 (04) : 112 - 121
[42] Radiotheranostics in advanced prostate cancer: Current and future directions
Jia, Angela Y. Y.
Kiess, Ana P.
Li, Qiubai
Antonarakis, Emmanuel S.
PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (01) : 11 - 21
[43] Current treatment and future directions for advanced pancreatic cancer
Rothenberg, ML
PANCREATIC CANCER: ADVANCES IN MOLECULAR PATHOLOGY, DIAGNOSIS & CLINICAL MANAGEMENT, 1998, : 157 - 164
[44] Radiotheranostics in advanced prostate cancer: Current and future directions
Angela Y. Jia
Ana P. Kiess
Qiubai Li
Emmanuel S. Antonarakis
Prostate Cancer and Prostatic Diseases, 2024, 27 : 11 - 21
[45] Current and future directions for the treatment of advanced thyroid cancer
Prasongsook, Naiyarat
ANNALS OF ONCOLOGY, 2019, 30 : 70 - 70
[46] The current status of checkpoint inhibitors in metastatic bladder cancer
Fahmy, Omar
Khairul-Asri, Mohd Ghani
Stenzl, Arnulf
Gakis, Georgios
CLINICAL & EXPERIMENTAL METASTASIS, 2016, 33 (07) : 629 - 635
[47] The current status of checkpoint inhibitors in metastatic bladder cancer
Omar Fahmy
Mohd Ghani Khairul-Asri
Arnulf Stenzl
Georgios Gakis
Clinical & Experimental Metastasis, 2016, 33 : 629 - 635
[48] Molecular Cancer Prevention: Current Status and Future Directions
Maresso, Karen Colbert
Tsai, Kenneth Y.
Brown, Powel H.
Szabo, Eva
Lippman, Scott
Hawk, Ernest T.
CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (05) : 345 - 383
[49] Cancer stem cells: Current status and future directions
Stoica, George
VETERINARY JOURNAL, 2015, 205 (02): : 124 - 125
[50] Lapatinib: Current status and future directions in breast cancer
Moy, Beverly
Goss, Paul E.
ONCOLOGIST, 2006, 11 (10): : 1047 - 1057

← 1 2 3 4 5 →